---
figid: PMC8867675__12943_2022_1534_Fig2_HTML
figtitle: Integration of liquid biopsy and pharmacogenomics for precision therapy
  of EGFR mutant and resistant lung cancers
organisms:
- Rat sarcoma virus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8867675
filename: 12943_2022_1534_Fig2_HTML.jpg
figlink: /pmc/articles/PMC8867675/figure/Fig2/
number: F2
caption: 'Schematic diagram explaining mechanisms of acquired resistance to EGFR TKIs.
  A. Mutant EGFR confers resistance to binding of TKIs to the tyrosine kinase domain
  of EGFR. This activates downstream signaling pathways such as the PI3K-AKT pathway,
  JAK-STAT pathway, RAS pathway and ERK-MAPK pathway. B. Overexpression of HGF causes
  TKI-resistance that activates downstream signaling of the PI3K-AKT pathway, JAK-STAT
  pathway, RAS pathway and ERK-MAPK pathway. The above pathways result in cell proliferation,
  cell migration, invasion, and metastasis, that in turn cause the release of CTCs,
  ctDNA, miRNA, lncRNA, exosomes and TEPs into the bloodstream. Liquid biopsy helps
  examine these biomarkers and assess the type of mutation. Created with BioRender.com
  (Agreement number: XF237SHT72). Abbreviations: EGFR: Epidermal growth factor receptor;
  TK: Tyrosine kinase; CTCs: Circulating tumor cells; ctDNA: Circulating tumor DNA;
  miRNA: Micro RNA; lncRNA: Long non-coding RNA; TEPs: Tumor educated platelets; mTOR:
  Mammalian target of rapamycin; AKT: V-akt murine thymoma viral oncogene homolog;
  PI3K: Phosphoinositide 3-kinase; STAT3: Signal transducer and activator of transcription
  3; JAK: Janus Activated Kinase; ERK: Extracellular-signal-regulated kinase; MAPK:
  Mitogen-activated protein kinase; MEK: Mitogen-activated protein kinase kinase;
  RAF: Rapidly Accelerated Fibrosarcoma; RAS: Rat sarcoma virus; HGF: Hepatocyte growth
  factor; TKIs: Tyrosine kinase inhibitors; MET: Mesenchymal epithelial transition
  factor'
papertitle: Integration of liquid biopsy and pharmacogenomics for precision therapy
  of EGFR mutant and resistant lung cancers.
reftext: Jill Kolesar, et al. Mol Cancer. 2022;21:61.
year: '2022'
doi: 10.1186/s12943-022-01534-8
journal_title: Molecular Cancer
journal_nlm_ta: Mol Cancer
publisher_name: BioMed Central
keywords: EGFR | Liquid biopsy | Lung cancer | Pharmacogenomics | Precision therapy
  | Tyrosine kinase inhibitors
automl_pathway: 0.9025968
figid_alias: PMC8867675__F2
figtype: Figure
redirect_from: /figures/PMC8867675__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8867675__12943_2022_1534_Fig2_HTML.html
  '@type': Dataset
  description: 'Schematic diagram explaining mechanisms of acquired resistance to
    EGFR TKIs. A. Mutant EGFR confers resistance to binding of TKIs to the tyrosine
    kinase domain of EGFR. This activates downstream signaling pathways such as the
    PI3K-AKT pathway, JAK-STAT pathway, RAS pathway and ERK-MAPK pathway. B. Overexpression
    of HGF causes TKI-resistance that activates downstream signaling of the PI3K-AKT
    pathway, JAK-STAT pathway, RAS pathway and ERK-MAPK pathway. The above pathways
    result in cell proliferation, cell migration, invasion, and metastasis, that in
    turn cause the release of CTCs, ctDNA, miRNA, lncRNA, exosomes and TEPs into the
    bloodstream. Liquid biopsy helps examine these biomarkers and assess the type
    of mutation. Created with BioRender.com (Agreement number: XF237SHT72). Abbreviations:
    EGFR: Epidermal growth factor receptor; TK: Tyrosine kinase; CTCs: Circulating
    tumor cells; ctDNA: Circulating tumor DNA; miRNA: Micro RNA; lncRNA: Long non-coding
    RNA; TEPs: Tumor educated platelets; mTOR: Mammalian target of rapamycin; AKT:
    V-akt murine thymoma viral oncogene homolog; PI3K: Phosphoinositide 3-kinase;
    STAT3: Signal transducer and activator of transcription 3; JAK: Janus Activated
    Kinase; ERK: Extracellular-signal-regulated kinase; MAPK: Mitogen-activated protein
    kinase; MEK: Mitogen-activated protein kinase kinase; RAF: Rapidly Accelerated
    Fibrosarcoma; RAS: Rat sarcoma virus; HGF: Hepatocyte growth factor; TKIs: Tyrosine
    kinase inhibitors; MET: Mesenchymal epithelial transition factor'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - STAT3
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - TK1
  - TK2
  - MDFI
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - KRAS
  - HRAS
  - NRAS
  - HGF
  - IL6
  - SOS1
  - Egfr
  - Mtor
  - Tor
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - oc
  - hop
  - bsk
  - Tk
  - svp
  - Dsor1
  - Mtk
  - Raf
  - ras
  - Ras64B
  - Ras85D
---
